'Adverse event profile' diaporamas de présentation

689 views • 36 slides

FDA Review of NDA 21-304 Valganciclovir for the Treatment of CMV Retinitis in AIDS

FDA Review of NDA 21-304 Valganciclovir for the Treatment of CMV Retinitis in AIDS. Joseph Toerner, MD Medical Officer DAVDP. EFFICACY Induction therapy W V15376 Maintenance therapy Pharmacokinetic data. SAFETY Study W V15376 Study W V15705 Single-arm safety study Study PV16000

584 views • 34 slides

The VentrAssist U.S. Pivotal Bridge to Cardiac Transplantation Trial

The VentrAssist U.S. Pivotal Bridge to Cardiac Transplantation Trial. A Boyle, N Moazami, R John, G Ewald, A Anyanwu, S Pinney, S Desai, N Burton, J Teuteberg, R Kormos, M Parides, A Gelijns, D Ascheim, U Rawiel, L Joyce, and the VentrAssist Investigators

401 views • 29 slides

E001451 Primary 1 6/9/2014

805 views • 22 slides

SARC015: Phase II study of R1507 in wild-type GIST

SARC015: Phase II study of R1507 in wild-type GIST. Margaret von Mehren, Fox Chase Cancer Center Katie Janeway, Dana Farber Cancer Institute. 10% of GISTs in adults and 85% of GISTs in pediatric patients are wild-type (WT) TKIs in WT GIST TKIs in pediatric GIST

293 views • 12 slides